Market News

4 Stocks Insiders Are Buying



AbbVie confident of blockbuster drug replacements, lifts profit view third time

(Reuters) -U.S. drugmaker AbbVie Inc on Friday raised its 2021 adjusted profit forecast for the third time this year and said it expects its newer drugs to recreate the success of its blockbuster treatment Humira over the next few years. The company has been focusing on gaining expanded approvals and driving growth for Skyrizi and Rinvoq, launched in 2019, as it prepares for competition from U.S. rivals to Humira, the world’s biggest selling medicine, in 2023. One of the new drugs, however, has come under some pressure since the U.S. drug regulator in September asked AbbVie and some rivals to include information about the risk of serious conditions and death from use of drugs that belong to a class of treatments known as JAK inhibitors, including Rinvoq.

Earnings results so far show companies are effectively navigating supply issues and rising costs

Previous article

Stocks making the biggest moves premarket: Chevron, Exxon Mobil, Newell Brands and more

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Market News